辉瑞拟100亿美元收购Metsera 诺和诺德退出竞购战

Core Viewpoint - Pfizer has agreed to acquire Metsera for $10 billion after a bidding war with Novo Nordisk, with Novo Nordisk deciding not to raise its offer [1] Group 1: Acquisition Details - Pfizer will purchase Metsera at a maximum price of $86.25 per share, which includes an initial cash payment of $65.60 per share and potential additional payments of up to $20.65 per share contingent on achieving specific milestones [1]